Acting FDA Chief Sharpless Pledges 'Full Speed Ahead' On Current Agenda
Executive Summary
In his first speech to agency staff, Acting Commissioner Norman Sharpless says FDA will continue working on issues including food safety and nutrition drug, and he is not approaching the post like a temporary caretaker. Sharpless said his appointment does not reflect attempt by President Trump or HHS Secretary Alex Azar to force FDA to change direction set by Scott Gottlieb.
You may also be interested in...
Former FDA Commissioners Push For Sharpless Nomination, Confirmation
Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.
Sharpless On FDA's Dietary Supplement Regulation Reform: It's 'Complicated'
"I look forward to beginning a productive dialogue about reshaping our oversight of these products," acting FDA Commissioner Norman Sharpless said recently about agency's public meeting on May 16. Access to meeting at CFSAN headquarters opens at 8 a.m. and irst of four sessions on questions center stated in meeting notice begins at 9 a.m. Each discussion followed by question and answer sessions and public comments scheduled for 3 p.m.
Gottlieb's Greatest Strength As US FDA Commissioner? Stability
Amid all the praise for his raising of FDA's profile and aggressive policy stances, Scott Gottlieb's most valuable contribution while in office may have been leaving the agency fundamentally unchanged, an important lesson for incoming Acting Commissioner Norman Sharpless.